CNBX Pharmaceuticals Reports Increased Net Losses and Financial Challenges for May 2026

CNBX Pharmaceuticals Inc. reported its financial results for the three and nine months ended May 31, 2026, revealing a net loss of $154,165 for the quarter and $311,982 for the nine-month period. This represents an increase in losses compared to the same periods in the previous year, where the company recorded a net loss of $59,727 for the quarter and $163,867 for the nine months. The company's total operating expenses for the three months ended May 31, 2026, were $162,763, significantly higher than the $40,380 reported in the same quarter of 2025, primarily due to increased general and administrative expenses.

In terms of liquidity, CNBX Pharmaceuticals had cash and cash equivalents of $9,487 as of May 31, 2026, down from $15,111 at the end of the previous fiscal year. The company reported cash used in operations of $125,624 for the nine months ended May 31, 2026, a slight improvement from $142,760 in the same period of 2025. The company generated $120,000 in cash from financing activities during the nine months ended May 31, 2026, compared to $129,992 in the prior year, indicating a reliance on external financing to support operations.

Strategically, CNBX Pharmaceuticals is focused on developing its proprietary drug candidate RCC-33 for colorectal cancer, with plans to initiate Phase I/II clinical trials in 2027. The company has also undergone significant changes in its capital structure, issuing 921,805,889 shares in connection with the conversion of loans and interest totaling $148,561 during the reporting period. This increase in shares outstanding reflects the company's ongoing efforts to manage its debt and raise capital.

Operationally, CNBX Pharmaceuticals has maintained a minimal workforce, with only one employee as of May 31, 2026. The company has not recorded any research and development expenses during the nine months ended May 31, 2026, which may indicate a focus on administrative costs rather than product development at this stage. The company’s ability to continue as a going concern is under scrutiny, as it has incurred cumulative losses of $25,580,358 since inception, raising concerns about its financial viability without additional capital.

Looking ahead, CNBX Pharmaceuticals acknowledges the need for further financing to support its operations and clinical development plans. The company has indicated that it may need to explore various funding options, including borrowing from shareholders or issuing equity, to meet its financial obligations. The outlook remains uncertain, as the company has not secured any arrangements for additional capital, which could significantly impact its ability to continue operations and pursue its strategic objectives.